Please use this identifier to cite or link to this item:
10.1186/s41181-023-00211-5
| Title: | Novel radionuclides for use in Nuclear Medicine in Europe : where do we stand and where do we go? |
| Authors: | Radzina, Maija Saule, Laura Mamis, Edgars Koester, Ulli Cocolios, Thomas Elias Pajuste, Elina Kalnina, Marika Palskis, Kristaps Sawitzki, Zoe Talip, Zeynep Jensen, Mikael Duchemin, Charlotte Leufgen, Kirsten Stora, Thierry Rīga Stradiņš University |
| Keywords: | Radionuclides;Diagnostic;Therapy;PET/CT;PRISMAP programme;3.2 Clinical medicine;1.1. Scientific article indexed in Web of Science and/or Scopus database |
| Issue Date: | Dec-2023 |
| Citation: | Radzina , M , Saule , L , Mamis , E , Koester , U , Cocolios , T E , Pajuste , E , Kalnina , M , Palskis , K , Sawitzki , Z , Talip , Z , Jensen , M , Duchemin , C , Leufgen , K & Stora , T 2023 , ' Novel radionuclides for use in Nuclear Medicine in Europe : where do we stand and where do we go? ' , EJNMMI Radiopharmacy and Chemistry , vol. 8 , no. 1 , 27 . https://doi.org/10.1186/s41181-023-00211-5 |
| Abstract: | BACKGROUND: In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational research. The aim of this article is to introduce readers with current status of novel radionuclides in Europe. MAIN BODY: A consortium questionnaire was disseminated through the PRISMAP consortium and user community, professional associations and preclinical/clinical end users in Europe and the current status of clinical end-users in nuclear medicine were identified. A total of 40 preclinical/clinical users institutions took part in the survey. Clinical end users currently use the following radionuclides in their studies: 177Lu, 68 Ga, 111In, 90Y, other alpha emitters, 225Ac, 64Cu and Terbium isotopes. Radionuclides that would be of interest for users within the next 2-5 years are 64Cu, Terbium radionuclide "family" and alpha emitters, such as 225Ac. CONCLUSIONS: Thanks to a questionnaire distributed by the PRISMAP consortium, the current status and needs of clinical end-users in nuclear medicine were identified. |
| Description: | Funding Information: PRISMAP “Production of high purity isotopes by mass separation” is the European medical isotope programme that federates a consortium of key European facilities such as intense neutron sources, isotope mass separation facilities and high-power accelerators and cyclotrons, with leading biomedical research institutes and hospitals active in the translation of the emerging radionuclides into medical diagnosis and treatment. PRISMAP creates a single-entry point for a fragmented user community distributed amongst universities, research centers, industry and hospitals, in a similar way as how the National Isotope Development Centre NIDC, supported by the Department of Energy (DOE), has provided radionuclide sources for users in the United States of America (USA). Funding Information: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101008571 (PRISMAP). This document reflects only the view of the author(s). The funding agenc(y/ies) is/are not responsible for any use that may be made of the information it contains. Publisher Copyright: © 2023, Springer Nature Switzerland AG. |
| DOI: | 10.1186/s41181-023-00211-5 |
| ISSN: | 2365-421X |
| Appears in Collections: | Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| Novel_radionuclides_for_use_in_Nuclear.pdf | 1.84 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.